Novartis is acquiring an FDA priority review voucher from Mallinckrodt Pharmaceuticals. The $100 million price tag is in the neighborhood of the going rate for these vouchers, which grant a company a shorter regulatory review timeline for a drug that addresses a rare or neglected disease.
BrightInsight developed the Disease Management Solution to help biopharma and medtech companies bring their Software as a Medical Device (SaMD) to market faster, according to BrightInsight CEO and Co-founder Dr. Kal Patel.
Don't miss out on this valuable opportunity to meet and discuss the latest trends and opportunities. Don't miss your chance to save with the Super Early Bird Rate.
Rising deal premiums and shrinking profit margins are threatening the sustainability of the traditional approach to mergers and acqusitions, according to a report by Accenture. The firm expects growth-minded companies will turn to other pathways.
Nearly half of health systems and physician groups in the U.S. are behind on their 2022 revenue goals, and healthcare executives are worried about increasing costs, shrinking margins and the impending recession, according to a new report. It also found that most healthcare organizations' revenue cycle or billing departments are struggling with labor shortages, leading operational inefficiencies and negative patient billing experiences.
Replace the tedious manual resume screening process! Learn how AI frameworks and technology are streamlining the recruiter/candidate experience, resulting in healthcare industries hiring skilled and knowledgeable personnel quickly and effectively.
No comments